(177 days)
Not Found
No
The summary describes a pneumatic compression device with a pump and controls, but makes no mention of AI or ML technologies.
Yes
The device is intended to treat and prevent various medical conditions and aid in physiological processes, such as preventing deep vein thrombosis, treating chronic venous insufficiency, healing ulcers, and aiding blood flow. These are all therapeutic applications.
No
The document describes the VPULSE as a device that provides intermittent external compression, designed to prevent and reduce complications of poor circulation and aid in healing. Its function is therapeutic, not diagnostic. It does not mention any capabilities for identifying, examining, or analyzing a disease or condition.
No
The device description explicitly states that the VPULSE system consists of a control unit, tubing set, and wraps, which are all hardware components. The control unit contains a pneumatic pump, air reservoir, and fluid pump.
Based on the provided information, the VPULSE device is not an IVD (In Vitro Diagnostic) device.
Here's why:
- IVD Definition: In vitro diagnostic devices are used to examine specimens taken from the human body, such as blood, urine, or tissue, to provide information about a person's health. This information is used for diagnosis, monitoring, or screening.
- VPULSE Function: The VPULSE is described as an intermittent, external compression device that applies pressure to the extremities. It works by physically aiding blood flow and reducing swelling.
- Lack of Specimen Analysis: The description of the VPULSE does not mention any analysis of biological specimens. It is a physical therapy device.
Therefore, the VPULSE falls under the category of a therapeutic device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The VPULSE is intended to function as an intermittent, external compression device in extremities to prevent and reduce complications of poor circulation. This includes:
- . deep vein thrombosis,
- chronic venous insufficiency, .
- . venous stasis ulcers,
- post-mastectomy edema and chronic lymphedema, .
- reduction of edema associated with soft tissue injuries such as burns, postoperative . edema, and ligament sprains,
- localized cold thermal therapy for post-traumatic and post-surgical medical and/or . surgical conditions)
- Aids the blood flow back to the heart .
- Treat and assist healing of cutaneous ulceration (wounds), reduce wound healing time, . enhance arterial circulation (blood flow), reduce compartmental pressures, reduce edema (swelling), reduce the need for anticoagulant (blood thinning) medications.
Product codes (comma separated list FDA assigned to the subject device)
JOW
Device Description
The VPULSE system is a device designed to function as a dual intermittent external pneumatic compression device. The intended therapies of the device are dynamic pneumatic compression therapy (DCT) in order to aid in the reduction and control of edema including lymphedema of the upper and lower extremities and venous stasis ulcers, and intermittent sequential pneumatic compression (SCT) in order to reduce the risk of the formation and prevent the occurrence of a pulmonary embolism resulting from a deep vein thrombosis (DVT) - collectively referred to as venous thromboembolism (VTE) - by aiding in the blood flow back to the heart via lower extremity limb compression.
The VPULSE system consists of a control unit, tubing set and a family of single-patient applied wraps.
The control unit contains a pneumatic pump and air reservoir for inflation of the DCT an SCT wraps, a fluid pump and user filled fluid canister for water circulation into the DCT wrap, and supporting controls to deliver and monitor the modalities. The control unit allows the patient to select and apply the treatment functions concurrently or individually.
The tubing set allows the patient to connect the wraps to the control unit and is of a length that allows treatment to be applied in a physical position comfortable for the user.
There are two (2) types of wraps given the intended treatment function of DCT and/or SCT. The DCT wraps are typically applied to an acute injury site usually the result of surgery. The SCT wraps are typically applied to the calves.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
extremities, upper and lower extremities, lower extremity limb, Calf
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
To demonstrate the performance of the Cothera VPULSE, bladder fatigue, static burst pressure, thermal, biocompatiblility, and inflation/deflation curve analysis were performed. In addition, adherence to applicable medical electrical equipment safety standards was demonstrated.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.5800 Compressible limb sleeve.
(a)
Identification. A compressible limb sleeve is a device that is used to prevent pooling of blood in a limb by inflating periodically a sleeve around the limb.(b)
Classification. Class II (performance standards).
0
510(k) Summary
FEB 2 2 2013
| Manufacturer: | Cothera
5796 Armada Drive
Ste. 250
Carlsbad, CA 92008 |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Date Prepared: | January 30, 2013 |
| Device Trade Name: | VPULSE |
| Contact: | Justin Eggleton
Musculoskeletal Clinical Regulatory Advisers, LLC
1331 H Street NW, 12th Floor
Washington, DC 20005
Office: 202.552.5800
Fax: 202.552.5798 |
| Classification: | 21 CFR §870.5800 |
| Class: | II |
| Product Code: | JOW |
Indications and Contraindications for Use:
The VPULSE is intended to function as an intermittent, external compression device in extremities to prevent and reduce complications of poor circulation. This includes:
- . deep vein thrombosis,
- chronic venous insufficiency, .
- . venous stasis ulcers,
- post-mastectomy edema and chronic lymphedema, .
- reduction of edema associated with soft tissue injuries such as burns, postoperative . edema, and ligament sprains,
- localized cold thermal therapy for post-traumatic and post-surgical medical and/or . surgical conditions)
- Aids the blood flow back to the heart .
- Treat and assist healing of cutaneous ulceration (wounds), reduce wound healing time, . enhance arterial circulation (blood flow), reduce compartmental pressures, reduce edema (swelling), reduce the need for anticoagulant (blood thinning) medications.
Image /page/0/Figure/15 description: The image contains the text "For Controlled Cold Therapy:". The text is in a serif font and is left-aligned. The text is likely a heading or title for a document or presentation about cold therapy.
Contraindications Patients should be aware of situations where cold therapy may not be appropriate, detrimental to a specific condition or otherwise contraindicated for use: Patients with specific cold sensitivity symptoms, such
1
Cothera VPULSE
K122640
as:
- Diabetes .
- Cold uticaria .
- . Cryoglobulinemia
- Raynaud's syndrome .
- . Proximal cold hemoglobinuria
- Vasospastic disease .
- Cold hypersensitivity
- Compromised local circulation
Patients should take caution in applying cold therapy over open sores and abrasions. At a minimum, these areas should be cleaned and bandaged.
When using the VPULSE, periodically check the skin where the pad is applied. Discontinue use if continued numbness, skin discoloration, blisters, etc. are present. Please refer to your healthcare professional prior to applying this system and / or using the system for extended periods of time.
| For Dvnamic Compression Therapy and Sequential Compression Therapy: | ||
|---|---|---|
| --------------------------------------------------------------------- | -- | -- |
Contraindications Patients with the following conditions should not use the VPULSE:
- Presumptive evidence of congestive heart . failure
- Suspected/observed pre-existing deep vein . thrombosis or pulmonary embolism
- Suspected/observed deep acute venal . thrombosis (phlebothrombosis)
- Suspected/observed inflammatory phlebitis . process
- Suspected/observed pulmonary edema .
- Suspected /observed pulmonary embolism .
- Suspected/observed acute inflammations of the . veins (thrombophlebitis)
- Suspected/observed decompensated cardiac . insufficiency
- Suspected/observed arterial dysregulation .
- Suspected/observed ervsipelas .
- Suspected/observed carcinoma and carcinoma . metastasis in the affected extremity
- Suspected/observed decompensated hypertonia .
- Suspected/observed acute inflammatory skin � diseases or infection
- . Suspected/observed venous or arterial occlusive disease
- Determined venous and lymphatic return is . undesirable
- Suspected/observed patient has Raynaud's Disease
2
- Suspected/observed poor peripheral circulation
- Suspected/observed hypersensitivity to cold
- Medical situations where increased venous and lymphatic return is undesirable
- . Leg gangrene
- Recent skin graft
- Patient therapy contact on extremity containing a fracture; or
- Extremities that are not sensitive to pain
Use with Caution and under direct supervision of a physician
- Extremities not sensitive to pain .
- Individuals with extremely low blood pressure
- Individuals with Raynaud's Disease
- Hypersensitivity to cold
- Children
- Diabetics
Device Description:
The VPULSE system is a device designed to function as a dual intermittent external pneumatic compression device. The intended therapies of the device are dynamic pneumatic compression therapy (DCT) in order to aid in the reduction and control of edema including lymphedema of the upper and lower extremities and venous stasis ulcers, and intermittent sequential pneumatic compression (SCT) in order to reduce the risk of the formation and prevent the occurrence of a pulmonary embolism resulting from a deep vein thrombosis (DVT) - collectively referred to as venous thromboembolism (VTE) - by aiding in the blood flow back to the heart via lower extremity limb compression.
The VPULSE system consists of a control unit, tubing set and a family of single-patient applied wraps.
The control unit contains a pneumatic pump and air reservoir for inflation of the DCT an SCT wraps, a fluid pump and user filled fluid canister for water circulation into the DCT wrap, and supporting controls to deliver and monitor the modalities. The control unit allows the patient to select and apply the treatment functions concurrently or individually.
The tubing set allows the patient to connect the wraps to the control unit and is of a length that allows treatment to be applied in a physical position comfortable for the user.
There are two (2) types of wraps given the intended treatment function of DCT and/or SCT. The DCT wraps are typically applied to an acute injury site usually the result of surgery. The SCT wraps are typically applied to the calves.
Predicate Device(s):
Predicate devices cited include the Thermotek NanoTherm™ and VascuTherm™ (K061866).
| Subject Device | Predicate Devices | |
|---|---|---|
| Manufacturer | Cothera | Thermotek |
| Trade Name | VPulse | NanoTherm, VascuTherm |
| Subject Device | Predicate Devices | |
| 510(k) Number | (Subject Device) | K061866 |
| Product Code | ||
| Regulation Number | JOW (21 CFR §870.5800) | JOW (21 CFR §870.5800) |
| Intended Use | The VPULSE is intended to function as an intermittent, external compression device in extremities to prevent and reduce complications of poor circulation. This includes: | |
| deep vein thrombosis, chronic venous insufficiency, venous stasis ulcers, post-mastectomy edema and chronic lymphedema, reduction of edema associated with soft tissue injuries such as burns, postoperative edema, and ligament sprains, localized thermal therapy (hot or cold) for post-traumatic and post-surgical medical and/or surgical conditions) Aids the blood flow back to the heart Treat and assist healing of cutaneous ulceration (wounds), reduce wound healing time, enhance arterial circulation (blood flow), reduce compartmental pressures, reduce edema (swelling), reduce the need for anticoagulant (blood thinning) medications. | The NanoTherm and VascuTherm systems are devices that are intended to function as intermittent, external pneumatic compression devices. |
The intended therapy of the NanoTherm device is to aid in the reduction and control of edema including lymphedema of the upper and lower extremities and venous stasis ulcers.
The intended therapy of the VascuTherm device is to reduce the risk of the formation of deep venous thrombosis (DVT) by aiding in blood flow back to the heart via lower extremity limb compression in addition to the intended uses of the NanoTherm device. |
| Cycle Time | 80 seconds | 60 seconds |
| Inflation Time | 10 seconds (Sequential Compression) | 30 seconds (DVT)
20 seconds (Edema/Lymphedema Therapy) |
| Deflation Time | 70 seconds (Sequential Compression) | 30 seconds (DVT)
40 seconds (Edema/Lymphedema Therapy) |
| Pump Pressure
Range | 2-60 mm Hg +/- 20% (DVT)
2-50 mm Hg (Dynamic Compression – Edema/Lymphedema Therapy) | 45-100 mm Hg +/- 5 mm Hg (DVT)
30 mm Hg +/- 5 mm Hg (Edema/Lymphedema Therapy) |
| Default Pressure | 60 mm Hg (DVT, Calf)
50 mm Hg (Edema/Lymphedema Therapy) | 45 mm Hg (DVT, Calf)
30 mm Hg (Edema/Lymphedema Therapy) |
| Therapy Temperature
Range | Cold: 41F minimum, 80F maximum | Heat: 105F
Cold: 43F to 49F |
| Sterility (Wrap) | Non-Sterile | Non-Sterile |
| Biocompatibility | ISO 10993-1, 5, 10 | ISO 10993-1 |
| Single Patient Use
(Wrap) | Yes | Yes |
| Safety | IEC 60601-1 (General Requirements for Medical Electrical Equipment) | IEC 60601-1 (General Requirements for Medical Electrical Equipment) |
| Subject Device | Predicate Devices | |
| IEC 60101-1-2 (Medical Electrical
Equipment: Collateral Standard) | IEC 60601-1-1 (Emissions, Class A) | |
| | IEC 60601-1-2 (Immunity) | |
3
.
,
.
.
4
Cothera VPULSE
Page 19 of 485
Performance:
To demonstrate the performance of the Cothera VPULSE, bladder fatigue, static burst pressure, thermal, biocompatiblility, and inflation/deflation curve analysis were performed. In addition, adherence to applicable medical electrical equipment safety standards was demonstrated.
Conclusion:
The Cothera VPULSE has been shown to be substantially equivalent to predicates in the above described indications, performance parameters, and safety parameters.
5
Image /page/5/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird-like symbol with three curved lines forming its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the bird symbol. The text is in all caps and appears to be in a sans-serif font.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002
February 22, 2013
Cothera, LLC c/o Mr. Justin Eggleton Musculoskeletal Clinical Regulatory Advisers, LLC 1331 H Street NW. 12th Floor Washington, DC 20005
Re: K122640
Trade/Device Name: VPULSE Regulation Number: 21 CFR 870.5800 Regulation Name: Compressible Limb Sleeve Regulatory Class: Class II Product Code: JOW Dated: January 30, 2013 Received: January 31, 2013
Dear Mr. Eggleton:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Ilisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
6
Page 2 - Mr. Justin Eggleton
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements. including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safetv/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Matthew G.Hillebrenner
for
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
7
Indications for Use
510(k) Number (if known):
Device Name: Cothera VPULSE
The VPULSE is intended to function as an intermittent, external compression device in extremities to prevent and reduce complications of poor circulation. This includes:
- deep vein thrombosis. .
- chronic venous insufficiency, .
- venous stasis ulcers, .
- . post-mastectomy edema and chronic lymphedema,
- reduction of edema associated with soft tissue injuries such as burns. . postoperative edema, and ligament sprains,
- localized cold thermal therapy for post-traumatic and post-surgical medical . and/or surgical conditions)
- Aids the blood flow back to the heart .
- . Treat and assist healing of cutaneous ulceration (wounds), reduce wound healing time, enhance arterial circulation (blood flow), reduce compartmental pressures, reduce edema (swelling), reduce the need for anticoagulant (blood thinning) medications.
Prescription Use V (Part 29 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (29 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)